A comprehensive introduction to the drug fosdenopterin

Fosdenopterin (fosdenopterin), chemically named cyclic pyranopterin monophosphate (cPMP), is a synthetic precursor of molybdenum cofactor (MoCo). Its trade name is Nulibry®, which is produced by Origin from the United States. Developed by BiosciencesCompany, and obtained approval from the U.S. Food and Drug Administration ( pan>FDA) approved, becoming the world's first substrate replacement therapy drug for the treatment of A molybdenum cofactor deficiency (MoCD-A).

The drug needs to be in the range of -25°C to -10°CFrozen storage, after reconstitution, it can be stored at room temperature (15°C to 25°C) or refrigerated (2°C to 8°C) and stored for 4 hours (including infusion time). Avoid heating, shaking or refreezing the solution after reconstitution.

MoCD-A is a rare autosomal recessive disease caused by mutations in the MOCS1 gene, leading to an impairment in the synthesis of molybdenum cofactor (MoCo). MoCo is a member of a variety of molybdenum-dependent enzymes (such as sulfite oxidase (SOX), xanthine dehydrogenase/Essential cofactor for oxidase (XDH/XO) and aldehyde oxidase (AO). MoCo deficiency can lead to the following pathological processes:

Neurotoxic metabolite accumulation:SOX deficiency results in the inability to convert sulfite (SO₃²⁻) into sulfate (SO₄²⁻), triggering sulfite toxicity in the brain, leading to brain damage and seizures.

Abnormal purine metabolism:XDH/XO deficiency leads to reduced uric acid production, which may aggravate nervous system damage.

Other metabolic disorders:AO deficiency affects the metabolism of drugs and endogenous aldehydes, which may lead to drug toxicity or metabolic disorders.

Fosdenoprin provides exogenous cPMP to replace the endogenous cPMP synthesis defect caused by MOCS1 gene mutation. cPMP is converted into molybdopterin (MPT) through a two-step enzymatic reaction in the body, and then further converted into molybdenum cofactor (MoCo).

Step one:cPMP is catalyzed by MOCS2A/B enzyme to generate MPT.

Second step: MPT is combined with molybdate under the catalysis of MOCS3 enzyme to generate MoCo.

The generated MoCo is transported into the cell and combines with SOX, XDH/XO, AO and other enzymes to restore its catalytic activity. Specific mechanisms include:

SOX: Oxidizes sulfite to sulfate, reducing sulfite levels in the brain and reducing neurotoxicity.

XDH/XO: Participates in purine metabolism, maintains uric acid levels, and may have neuroprotective effects.

AO: Promote aldehyde metabolism and reduce the toxic accumulation of drugs or endogenous aldehydes.

Reference materials:https://nulibry.com/